{
  "docId": "019de076-05a8-756d-90c0-05335f3877b6",
  "docSlug": "06c66508aa113b26851e16e612e1d04c",
  "documentTitle": "Mainz Biomed NV | Investor Presentation Deck | 28 slides",
  "authorId": "mainz-biomed-nv",
  "authorName": "Mainz Biomed",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 3,
  "pageCount": 28,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 3,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-05a8-756d-90c0-05335f3877b6/3",
  "deckHref": "/decks/019de076-05a8-756d-90c0-05335f3877b6",
  "deckJsonHref": "/decks/019de076-05a8-756d-90c0-05335f3877b6.json",
  "deckAnchorHref": "/decks/019de076-05a8-756d-90c0-05335f3877b6#slide-3",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.3,
        "x": 0.03,
        "y": 0.55
      },
      "kind": "list",
      "text": "Disruptive next-gen product (in development): Expanding current test to add novel, proprietary mRNA biomarkers to increase the detection of advanced adenomas; Early detection of advanced adenomas (precancerous lesions) could drastically reduce or even eliminate cancer; Two ongoing clinical trials with data reported in 2023; planning to initiate recruitment for FDA PMA pivotal study in mid 2024",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4b1e8cf5-1911-49d6-bce5-0cd79f7ca998",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.3,
        "x": 0.67,
        "y": 0.55
      },
      "kind": "list",
      "text": "Strong intellectual property position: Valuable IP position, with new IP in development; Trade secret portfolio",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "afcc4ff3-38f7-4291-9738-401a99997bff",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.3,
        "x": 0.35,
        "y": 0.55
      },
      "kind": "list",
      "text": "Strong team: Experienced diagnostics team, formerly Roche, Abbott or Qiagen; took the company public in 2021; 64 employees with headquarters in Mainz, Germany; Strong Medical Advisory Board with renowned scientific and oncology experts",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c35abf5c-7bec-4da8-b6a4-100167a33218",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.3,
        "x": 0.67,
        "y": 0.15
      },
      "kind": "list",
      "text": "Disruptive, decentralized business model: Kit-based solution that allows the testing to be done in any lab across the United States; All competitors using CLIA laboratory based centralized solutions that require large investments to broadly commercialize the product nationally; Enables the sale of ColoAlert® internationally",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cd399112-1388-4a83-8971-b1f2a76b41f2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.3,
        "x": 0.35,
        "y": 0.15
      },
      "kind": "list",
      "text": "Significant market opportunity: $10bn+ global CRC market (3rd most-commonly diagnosed cancer; 2nd leading cause of cancer death globally); Ability to move into large, adjacent areas, including pancreatic cancer and other GI cancers",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e82fe410-8ea3-473b-b68d-b080d8f7c60e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.3,
        "x": 0.03,
        "y": 0.15
      },
      "kind": "list",
      "text": "Highly-differentiated flagship product (ColoAlert®): Highly efficacious, at-home, stool-based screening test for early colorectal cancer (CRC) detection; Combines a FIT test for detection of human hemoglobin with the PCR results of specific tumor DNA markers; Marketed as a CE-IVD product in Europe since 2021",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f3bbf262-17e2-4941-b2a9-e82ea2cb68a9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.25,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "Mainz Biomed Overview",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3571bcb5-f4ad-46e8-9358-6177a62b0359",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "02479f0f-407d-41e4-ace0-e40fe2944e4b",
      "evidence": "list/bullet: Disruptive next-gen product (in development): Expanding current test to add novel, proprietary mRNA biomarkers to increase the detection of advanced adenomas; Early detection of advanced adenomas (precancero",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}